Richmond Pharmacology will be attending the 5th Annual Cardiovascular Risk Assessment Summit taking place 26th to 27th January 2011 in Alexandria, Virginia.

Posted:
11
January 2011

Richmond Pharmacology will be attending the 5th Annual Cardiovascular Risk Assessment Summit taking place 26th to 27th January 2011 in Alexandria, Virginia.Cardiovascular toxicities and related adverse events continue to be one of the leading reasons why drugs are stopped in development and approved drugs are withdrawn from the market. Regulatory authorities have developed detailed guidelines on the importance of cardiac safety testing in the preclinical as well as in the clinical setting prior to market approval. This increased scrutiny of cardiac safety issues and the effect of regulations on the development process have made cardiac safety a top priority for pharmaceutical companies.2011 Program Highlights:

  • Hear an FDA Address on the analysis and interpretation of increases in blood pressure and heart rate
  • Learn results of the ICH meeting on ICH E14 requirements
  • Understand integrative preclinical and clinical perspectives on assessing adverse CV events
  • Improve precision, accuracy and predictive value of early clinical assessment
  • Discuss principal requirements of separating drug-induced and heart-rate-induced ECG changes
  • Hear an overview of novel electrophysiological biomarkers that can be used to predict proarrhythmic risk
  • Discuss serum and imaging biomarkers and their potential relevance in drug development
  • Assess the preclinical correlation of troponin elevation and myocardial injury

Dr J�rg T�ubel, medical practitioner and CEO of Richmond Pharmacology, will be hosting a speaker session scheduled for Day 2 of the conference at 08h50 on �What is New in the Design and Clinical Best Practice of TQT Studies�:Between 2006 and 2009 the FDA has reviewed 165 TQT studies performed since the adoption of ICH E14 guideline in 2005. In May 2010 they reported that 22 of those studies were rejected as inconclusive. There have been a large number of publications of TQT studies and this offers the opportunity to review the most effective approach to conduct definitive TQT studies.

  • Appraisal of the various studies published discussing which designs and processes yield best results
  • Proposals for high quality ECG acquisition and analysis
  • Proposals for alternative methods to assess assay sensitivity in TQT Studies

View full meeting programme: click here

Latest news

Upcoming Event

EUFEMED, 3rd Annual Conference, 28-30 April 2021

28-30 April 2021
Dr Jorg Taubel will co-chair a session on day one, which explores how technology has reduced the risks of pandemic effects on Phase I and II trial performance.
View event

Novel rate-controlled fentanyl patch shows promise in phase I clinical trial

April 1, 2021
Our expertise in ethnic differences and access to over 12,000 first generation Japanese volunteers accelerated our ability to provide robust clinical trial data to support future applications of new chronic pain medicines to the Japanese drug market.
Read more

A new era for UK-Japanese scientific relations

March 23, 2021
Dr Taubel uses his experience of conducting more than 60 Japanese bridging studies to explain why the deal is of strategic importance to the UK and highlights the scientific requirements for conducting successful Japanese trials abroad
Read more

Richmond Pharmacology’s local MP Neil Coyle calls on the Government to evaluate the potential of using Clinical Research Organisations.

February 3, 2021
Richmond Pharmacology has offered its services to the Government and the NHS as an additional vaccine site in London
Read more